The leading business intelligence provider, has released its latest research “The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global autoimmune diseases therapeutics market. The report analyzes the markets for autoimmune disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.
Scope Annualized market data for the autoimmune diseases therapeutics market from 2000 to 2008, forecast forward to 2015
Analysis of the leading therapeutic segments including rheumatoid arthritis, multiple sclerosis, systemic lupus, erythematosus, crohn’s disease and ulcerative colitis
Analysis of the autoimmune diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
Market characterization of the autoimmune diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
Key drivers and barriers that have a significant impact on the market
Coverage of pipeline molecules in various phases of drug development
Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Amgen Inc, AstraZeneca, Merck & Co, Pfizer Inc, Celgene Corporation, Bristol-Myers Squibb and Eli Lilly
Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global autoimmune diseases therapeutics market
For More Information Please Click :
http://www.aarkstore.com/reports/The-Future-of-Autoimmune-Diseases-Therapeutics- Or Call Us: 919272852585
Visit Our Blog: http://blogs.aarkstore.com
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.
Scope
Annualized market data for the autoimmune diseases therapeutics market from 2000 to 2008, forecast forward to 2015
Analysis of the leading therapeutic segments including rheumatoid arthritis, multiple sclerosis, systemic lupus, erythematosus, crohn’s disease and ulcerative colitis
Analysis of the autoimmune diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
Market characterization of the autoimmune diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
Key drivers and barriers that have a significant impact on the market
Coverage of pipeline molecules in various phases of drug development
Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Amgen Inc, AstraZeneca, Merck & Co, Pfizer Inc, Celgene Corporation, Bristol-Myers Squibb and Eli Lilly
Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global autoimmune diseases therapeutics market
For More Information Please Click :
http://www.aarkstore.com/reports/The-Future-of-Autoimmune-Diseases-Therapeutics-
Or Call Us: 919272852585
Visit Our Blog: http://blogs.aarkstore.com